Objective To examine the adverse events reported in the U.S. Food and Drug Administration's (U.S. FDA's) Manufacturer and User Facility Device Experience (MAUDE) database for prescription hearing aids (HA). Methods A retrospective study was performed from January 2014 to September 2024 using the U.S. FDA's MAUDE database. Medical device reports (MDRs) were identified using product codes (ESD, OSM, and QDD) and keywords ("Hearing Aid, Air-Conduction, Prescription; Hearing Aid, Air-Conduction with Wireless Technology, Prescription; and Self-fitting, Air-Conduction Hearing Aid, Prescription"). Exclusion criteria included reports unrelated to the usage of the device or those providing insufficient data. The incidence of adverse events was estimated using the Hearing Industries Association's market data over the last 10 years. Results A total of 586 medical device reports (MDRs) were identified, and 504 met the inclusion criteria. There were 4 (0.8%) MDRs identified in 2014, 7 (1.4%) in 2015, 7 (1.4%) in 2016, 11 (2.2%) in 2017, 7 (1.4%) in 2018, 27 (5.4%) in 2019, 50 (9.9%) in 2020, 24 (4.8%) in 2021, 119 (23.6%) in 2022, 174 (34.5%) in 2023, and 74 (14.7%) in 2024, up to the third quarter. Of the 504 MDRs, 829 total events were identified. The mean number of events per MDR was calculated as 1.9. Four hundred and ninety-four (59.6%) of the 829 events were related to device malfunction, with 180 (21.7%) attributed to charger-related issues and 137 (16.5%) to poor construction/device falling apart, resulting in foreign bodies in the ear for 96 (70.1%) of those 137 cases. A total of 303 (36.6%) events were related to adverse medical effects, 19 (2.3%) were related to customer service issues, and 11 (1.3%) were related to failure to provide hearing benefits. The incidence rate of adverse events over the last decade was calculated as 0.00114%. Conclusions There is a low reported incidence of adverse events associated with prescription hearing aids. Charger issues, possible poor construction and device failing apart, resulting in foreign bodies in the ear, and medical complications, were commonly reported as adverse events. The data can increase providers' awareness of common complaints, enhance targeted monitoring, and advise and manage expectations.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784808 | PMC |
http://dx.doi.org/10.7759/cureus.76737 | DOI Listing |
JMIR Res Protoc
March 2025
Institute for Data Science and Informatics, University of Missouri, Columbia, MO, United States.
Background: Amyotrophic lateral sclerosis (ALS) leads to rapid physiological and functional decline before causing untimely death. Current best-practice approaches to interdisciplinary care are unable to provide adequate monitoring of patients' health. Passive in-home sensor systems enable 24×7 health monitoring.
View Article and Find Full Text PDFBlood
March 2025
Vanderbilt UniversityVanderbilt-Meharry Center of Excellence in Sickle Cell Disease, Nashville, Tennessee, United States.
Recurrent ischemic priapism is a common complication of sickle cell anemia (SCA) and is associated with devastating physical and psychosocial consequences. All previous trials for priapism prevention have failed to demonstrate clear efficacy. We conducted a randomized, controlled, double-blind phase 2 feasibility trial comparing fixed moderate-dose hydroxyurea plus placebo (usual care arm) versus fixed moderate-dose hydroxyurea plus tadalafil (experimental arm) in 64 men (18- 40 years) with at least three episodes of SCA-related priapism in the past 12 months.
View Article and Find Full Text PDFPediatr Infect Dis J
March 2025
Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama.
Background: Congenital cytomegalovirus is the leading cause of nongenetic sensorineural hearing loss. Treatment with (val)ganciclovir improves audiologic outcomes. Neutropenia is a common adverse event, but correlates that predict who will develop neutropenia have not been identified.
View Article and Find Full Text PDFBlood
March 2025
Sungkyunkwan university school of medicine, Samsung Medical Center, Seoul, Korea, Republic of.
This study aimed to assess the efficacy and safety of combining cemiplimab, an anti-PD1 antibody, with isatuximab, an anti-CD38 antibody, in relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL). The hypothesis was that CD38 blockade could enhance the antitumor activity of PD1 inhibitors. Eligible patients received cemiplimab (250 mg on days 1 and 15) and isatuximab (10 mg/kg on days 2 and 16) intravenously every four weeks for six cycles.
View Article and Find Full Text PDFN Engl J Med
March 2025
Department of Disease Control, London School of Hygiene and Tropical Medicine, London.
Background: Hospital studies suggest that scrub typhus is a leading cause of severe undifferentiated fever in regions across Asia where the disease is endemic, but the population-based incidence of infection and illness has been little studied.
Methods: We conducted a population-based cohort study to assess epidemiologic and clinical characteristics of scrub typhus in 37 villages in Tamil Nadu, India, where the disease is highly endemic. Study participants were visited every 6 to 8 weeks over a period of 2 years; a venous blood sample was obtained from those who had had fever since the last visit.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!